Don't miss

Replay


LATEST SHOWS

EYE ON AFRICA

Togo : will president Faure Gnassingbe win a third 5-year term ?

Read more

MEDIAWATCH

Controversy reigns 100 years after the Armenian genocide

Read more

THE WORLD THIS WEEK

Migrant Deaths: Politicians Divided after Emergency EU Summit

Read more

THE WORLD THIS WEEK

The G-Word: Turkey and the Armenian Genocide

Read more

FRANCE IN FOCUS

What will the new French healthcare bill change?

Read more

#TECH 24

Space Special: Happy Birthday, Hubble!

Read more

FOCUS

Video: Meeting Marseille's Armenian community

Read more

REPORTERS

Saving French soldiers' WWI trench carvings

Read more

ENCORE!

Armenia, 100 years on

Read more

China seeks volunteers for AIDS vaccine trials

Latest update : 2009-03-21

China, where between 30 and 50 million people may be at risk from the disease, is seeking volunteers to undergo a second phase of human trials on an AIDS vaccine.

AFP - Chinese scientists are seeking volunteers to undergo a second phase of human trials on an AIDS vaccine, state media reported Saturday.

China began research into an AIDS vaccine 13 years ago and conducted its first phase of clinical trials on 49 people aged between 18 and 50 in the Guangxi region of southern China in 2005, the Xinhua news agency said.

"The recipients of the vaccine do not show any signs of adverse effects. Immune tests for the vaccine have also proved favourable results," said Kong Wei, one of the programme's team leaders.

Researchers said they wanted to enroll another 30 volunteers for the second phase of tests for the vaccine, which must undergo three lots of clinical trials before it can be approved for use.

Officially, China had 276,630 AIDS cases in 2008 and 38,100 deaths, but experts say the true figure is much higher as the tally refers only to confirmed incidents of the condition.

UNAIDS estimates that between 30 and 50 million people may be at risk from the disease in China, where transmission through sexual activity is increasingly common.
 

Date created : 2009-03-21

COMMENT(S)